Zobrazeno 1 - 10
of 181
pro vyhledávání: '"Ingegerd Hellstrom"'
Purpose: Immunomodulatory mAbs can treat cancer, but cures are rare except for small tumors. Our objective was to explore whether the therapeutic window increases by combining mAbs with different modes of action and injecting them into tumors.Experim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::619f6241c81db2ce1eab08916b7f0b43
https://doi.org/10.1158/1078-0432.c.6524499.v1
https://doi.org/10.1158/1078-0432.c.6524499.v1
Expression of surface molecules in TIL of mice receiving mAb combinations.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43c3172a746f365cc4b8a948a0ec8d01
https://doi.org/10.1158/1078-0432.22460463.v1
https://doi.org/10.1158/1078-0432.22460463.v1
Expression of surface molecules in TLN and spleen of mice receiving the mAb treatments.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c6c1da687c0cc5608fcb1c1e1c46d18
https://doi.org/10.1158/1078-0432.22460469.v1
https://doi.org/10.1158/1078-0432.22460469.v1
Depleted of CD19 cells by the 4 mAb combination.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b3a4a4cd2d9862887e23a3eb874b869
https://doi.org/10.1158/1078-0432.22460466.v1
https://doi.org/10.1158/1078-0432.22460466.v1
Figure legends for four supplementary figures.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69a1e2f65f356c6cfdb6286c9d15e522
https://doi.org/10.1158/1078-0432.22460460
https://doi.org/10.1158/1078-0432.22460460
Autor:
Huafeng Wei, Likun Zhao, Wei Li, Kexing Fan, Weizhu Qian, Sheng Hou, Hao Wang, Min Dai, Ingegerd Hellstrom, Karl Erik Hellstrom, Yajun Guo
Publikováno v:
PLoS ONE, Vol 8, Iss 12, p e84927 (2013)
There is an urgent need for improved therapy for advanced ovarian carcinoma, which may be met by administering immune-modulatory monoclonal antibodies (mAbs) to generate a tumor-destructive immune response. Using the ID8 mouse ovarian cancer model, w
Externí odkaz:
https://doaj.org/article/fd69ef8574f749bb9ca0604b9da7b7b9
Publikováno v:
Progress in molecular biology and translational science. 164
Several decades ago we published some of the first papers showing that both murine and human cancers are recognized in vitro as immunologically foreign and that this is the case also in the presence of a growing tumor. The latter situation, sometimes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5eb16ca470177bb919e494928a90a8da
https://pubmed.ncbi.nlm.nih.gov/31383402
https://pubmed.ncbi.nlm.nih.gov/31383402
Autor:
Ingegerd Hellstrom, B. Karlan, Nicole Urban, Nathalie Scholler, K.E. Hellstrom, Martin W. McIntosh, Charles W. Drescher
Publikováno v:
Gynecologic Oncology. 95:9-15
Objectives. The serum tumor marker CA 125 is elevated in most clinically advanced ovarian carcinomas. Because these elevations may precede clinical detection by a year or more, CA 125 is potentially useful for early detection as part of an ovarian ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff8a9855cc247d4427fcaecc8bcf8e51
https://doi.org/10.1016/j.ygyno.2004.07.039
https://doi.org/10.1016/j.ygyno.2004.07.039
Autor:
Edward N. Atkinson, Rosemarie Schmandt, Regina S. Whitaker, Karen H. Lu, Rebecca T. Marquez, David I. Smith, Gordon B. Mills, David M. Gershenson, Lin Wang, Ingegerd Hellstrom, Andrea P. Patterson, Jinsong Liu, Keith A. Baggerly, David A. Fishman, Robert C. Bast, Daniel G. Rosen, Lance R. Ramoth, Andrew Berchuck, Lynn C. Hartmann
Publikováno v:
Clinical Cancer Research. 10:3291-3300
Purpose: Advanced-stage epithelial ovarian cancer has a poor prognosis with long-term survival in less than 30% of patients. When the disease is detected in stage I, more than 90% of patients can be cured by conventional therapy. Screening for early-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef7b0cb9238bf2141ccd945203935acf
https://doi.org/10.1158/1078-0432.ccr-03-0409
https://doi.org/10.1158/1078-0432.ccr-03-0409
Autor:
Stephen J. Iturria, Patrick C. Roche, William A. Cliby, Lynn C. Hartmann, Ingegerd Hellstrom, Amy C. Clayton, Gregory M. Lubiniecki, Prema P. Peethambaram, Scott E. Strome
Publikováno v:
Gynecologic Oncology. 89:99-104
Objective Our objective was to determine if the level of Her-2/neu expression in advanced ovarian cancer changed after platinum-based chemotherapy. Methods Tissue samples from 43 patients who had surgery for ovarian cancer between 1991 and 2001 at th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::287a067441cbe3f077f24e4aafda09a6
https://doi.org/10.1016/s0090-8258(03)00065-9
https://doi.org/10.1016/s0090-8258(03)00065-9